VLP-based bivalent Ebola vaccines and methods of making and using same
AssigneeChildren's Hospital Medical Center
InventorsKarnail Singh, Paul Spearman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
Claims14
A method of making a bivalent VLP composition, comprising
- a. purifying from a cell line culture a VLP composition comprising a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins, wherein said at least two Ebola glycoproteins are incorporated into the surface of said spherical Gag protein core;
- wherein said cell line is stably transfected with
- a first plasmid containing a gag sequence under the control of an inducible promoter,
- a second plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter, and
- a third plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter,
- wherein said second and third plasmid contain different Ebola glycoproteins.
A composition comprising a cell line comprising a first plasmid containing a sequence encoding for a gag protein under the control of an inducible promoter, a second plasmid containing a sequence encoding for a first Ebola glycoprotein under the control of an inducible promoter, and a third plasmid containing a sequence encoding for a second Ebola glycoprotein under the control of an inducible promoter.
Dependencies are inferred from the claim text.